- RecruitingPHASE1, PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
This study looks at new ways to treat ovarian cancer that has come back after earlier treatments. It tests a new drug called Raludotatug deruxtecan (R-DXd) by itself or with other standard treatments, to see if it's safe and helps shrink the cancer.
For: Ovarian Cancer RecurrentUnited States · Canada · Israel - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
This study is testing a new drug (INCA33890) alongside standard chemotherapy and another medicine (bevacizumab) for advanced bowel cancer that has spread. It aims to see if adding INCA33890 is safe and helps people live longer and feel better.
For: CRC (Colorectal Cancer)United States · Argentina · Australia - Active not recruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
For: Hepatocellular Carcinoma · Biliary Tract CancerUnited States · China · Hong Kong - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
For: Hepatocellular CarcinomaUnited States · Australia · Brazil - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
For: Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal NeoplasmsUnited States · Australia · Austria - RecruitingPHASE3
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
This study is testing new ways to treat advanced bowel cancer (colorectal cancer) that has spread to other parts of the body. It compares a new drug, Precem-TcT, alone or with another treatment called bevacizumab, against a standard treatment, to see which works best.
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
This study is testing a new cancer medicine, AZD5335, on its own and with other treatments for various solid tumors. Researchers want to see if it's safe, tolerable, and if it can shrink tumors or stop them from growing. It's for people with advanced cancer.
For: Ovarian Cancer · Lung Adenocarcinoma · Endometrial CancerUnited States · Australia · Canada - RecruitingPHASE2
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
This study is testing a new combination of medicines for advanced bowel cancer. It aims to see how safe and effective a new drug, telisotuzumab adizutecan, is when given with standard treatments. The study will look at side effects and whether the cancer activity changes.
For: Metastatic Colorectal CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
This study is looking at a new treatment for certain types of ovarian, fallopian tube, or peritoneal cancer that have returned after initial treatment. It compares a new drug, mirvetuximab soravtansine, given with bevacizumab, against bevacizumab alone, to see if the new combination can keep the cancer away for longer.
For: Ovarian Cancer · Peritoneal Cancer · Fallopian Tube CancerUnited States · Argentina · Australia - RecruitingPHASE3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
This study looks at a new drug, Trastuzumab Deruxtecan, combined with an existing treatment, Bevacizumab, for a type of advanced ovarian cancer. It aims to see if this combination works better than Bevacizumab alone after initial chemotherapy.
For: Ovarian CancerUnited States · Australia · Austria - RecruitingPHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
This study is testing a new drug, Ris-Rez, for people with advanced cancers. Researchers want to see if it's safe, how it works, and if it can help stop cancer growth, both alone and with other medicines.
For: NeoplasmsUnited States · Argentina · Canada - RecruitingPHASE3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
This study offers continued treatment to cancer patients already in certain Genentech/Roche studies. It's for those still benefiting from their current treatment and who can't get it elsewhere. The aim is to bridge care for these patients.
For: CancerBelgium · Canada · China - RecruitingPHASE1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This study looks at new treatments for bowel cancer that has spread. We want to see if these targeted medicines or immunotherapy are safe and work well for people whose cancer has specific genetic features, which we call biomarkers.
For: Metastatic Colorectal CancerUnited States · Australia · Canada - RecruitingPHASE2, PHASE3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
This study is looking at a new treatment called pumitamig, combined with chemotherapy, for people with advanced bowel cancer that hasn't been treated before. It's being compared to a standard treatment, bevacizumab with chemotherapy, to see which is safer and more effective.
For: Untreated, Unresectable, or Metastatic Colorectal CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
This study is for people with advanced bowel cancer where previous chemotherapy hasn't worked. It compares a new drug called amivantamab, plus standard FOLFIRI chemotherapy, against other established treatments (cetuximab or bevacizumab) with FOLFIRI, to see which works best.
For: Colorectal NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
This study is looking at new ways to treat advanced liver cancer that can't be removed by surgery. It combines existing medications with a new one to see if this mix works better and is safe. The aim is to find improved first-line treatments for this type of cancer.
For: Hepatocellular CarcinomaUnited States · Belgium · Brazil - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.
For: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
For: Colorectal NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
This study is for women with cervical cancer that has spread. It's testing new combinations of medicines (sac-TMT, pembrolizumab, and possibly bevacizumab) to see if they are safe and can help people live longer or stop their cancer from getting worse.
For: Cervical CancerUnited States · Argentina · Austria - RecruitingPHASE3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
This study is for women with advanced ovarian cancer that has responded well to initial treatment. It's testing a new medicine called sac-TMT, sometimes with bevacizumab, to see if it can keep the cancer from growing or coming back for longer than standard care.
For: Ovarian Neoplasms · Ovarian CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
For: Colon Adenocarcinoma · Rectal AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has spread and has a specific gene change (BRAF). It compares these new combinations with standard chemotherapy to see which works best for people who haven't had treatment for their spread cancer.
For: NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE4
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
This study, called FLOTILLA, offers continued access to cancer medicines encorafenib and binimetinib for people who have already taken part in earlier clinical trials. It's for those still benefiting from the treatment.
For: Solid TumorsUnited States · Australia · Brazil - RecruitingPHASE3
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
This study is looking at a new medicine called Mocertatug Rezetecan (Mo-Rez) for women with ovarian cancer that hasn't responded well to previous platinum-based treatments. It aims to see if Mo-Rez works better or is safer than current standard treatments. It's a key step in understanding this new option.
For: Ovarian NeoplasmsAustralia · Canada · Japan - RecruitingPHASE1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
This study is testing a new medicine, INCA33890, for people with advanced or spreading solid cancers. Doctors want to see how safe the medicine is, what side effects it causes, and find the best dose to give.
For: Solid Tumors · Advanced Solid Tumors · Metastatic Solid TumorsUnited States · China · Denmark - Active not recruitingPHASE3
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
This study looks at treating stage 2 colon cancer after surgery. It compares standard chemotherapy with chemotherapy plus a drug called bevacizumab. The aim is to see if adding bevacizumab helps people stay cancer-free for longer.
For: Colon Adenocarcinoma · Stage IIA Colon Cancer AJCC v7 · Stage IIB Colon Cancer AJCC v7United States · Canada · Peru - Active not recruitingPHASE2
Bevacizumab Treatment For Type 1 ROP
This study looks at a special medicine (bevacizumab) for severe ROP, a eye condition in premature babies. We want to find the best low dose to help blood vessels grow normally and prevent vision problems, comparing two different amounts of the medicine.
For: Retinopathy of PrematurityUnited States · Canada - Active not recruitingPHASE1
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
This study looks at a new drug, ABBV-400, for advanced cancers like lung and bowel cancer. We're checking how safe it is and if it helps shrink tumours, both on its own and with another drug.
For: Non-Small Cell Lung Cancer · Advanced Solid Tumors · Gastroesophageal AdenocarcinomaUnited States · Australia · France - Active not recruitingPHASE3
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
This study looks at different ways to treat advanced ovarian, fallopian tube, or primary peritoneal cancer. It compares two chemotherapy treatments, with or without an additional drug called bevacizumab, to see which works best and has the fewest side effects.
For: Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma · Fallopian Tube Transitional Cell CarcinomaUnited States · Canada · South Korea - Active not recruiting
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
This study looks at how well different treatments work for adults with liver cancer that can't be removed by surgery. Researchers are collecting health information from medical records to find the best next steps for people who have already had a specific type of first-line therapy.
For: Unresectable Hepatocellular CarcinomaUnited States · Argentina · Brazil - RecruitingPHASE3
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
This study compares two treatments for a type of liver cancer called hepatocellular carcinoma (HCC) in its intermediate stage. It looks at a combination of two drugs, atezolizumab and bevacizumab, against a standard treatment called TACE (Transarterial Chemoembolization), to see which works best and is safest.
For: Hepatocellular CarcinomaAustria · France · Germany - Active not recruitingPHASE3
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
This study is looking at a new treatment for liver cancer to stop it coming back after surgery or other procedures. It compares two drugs, atezolizumab and bevacizumab, with regular check-ups to see which is better at preventing the cancer from returning.
For: Carcinoma, HepatocellularUnited States · Australia · Austria - RecruitingPHASE2, PHASE3
Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations
This study looks into a new drug, Bevacizumab, for people with brain AVMs causing symptoms like headaches or weakness. We want to see if this treatment can help reduce these symptoms, especially for those who can't have surgery.
For: Cerebral AV MalformationFrance - RecruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This study is testing a new drug, VVD-133214, for advanced solid tumours, including a type of bowel cancer. It looks at safety, how the body handles the drug, and if it can help shrink tumours. It's an early-stage study, sometimes testing the new drug with other standard treatments.
For: Advanced Solid Tumors · Colorectal CancerUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
This study looks at new ways to treat a serious type of brain cancer called glioblastoma. It combines a new drug (olaptesed pegol) with standard treatments like radiotherapy, aiming to improve outcomes for patients where usual chemotherapy isn't expected to work as well.
For: GlioblastomaGermany - RecruitingPHASE2
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
This study is testing two new drug combinations for advanced bowel cancer that has spread, but not actively to the liver. It aims to see if a new combination of two medicines, Fruquintinib and Tislelizumab, works better than standard treatment for this type of cancer.
For: Metastatic Colorectal CancerAustria · Germany - RecruitingPHASE2
Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
This study is looking at two different medicine combinations for bowel cancer that has spread. It compares panitumumab with trifluridine/tipiracil against bevacizumab with trifluridine/tipiracil, to see which works better as a first treatment.
For: Metastatic Colorectal CancerGermany - RecruitingPHASE2
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
This study is testing new treatments for a type of advanced bowel cancer that has spread. It compares a new drug called Volrustomig combined with standard chemotherapy and another drug (FOLFIRI and Bevacizumab) against the standard treatment alone, to see if adding Volrustomig is safe and effective.
For: Metastatic Colorectal CancerUnited States · Australia · Canada - RecruitingPHASE2, PHASE3
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
This study is looking into new treatments for advanced liver cancer (hepatocellular carcinoma). It compares new drug combinations, livmoniplimab with budigalimab, against existing treatments to find the best dose and see how well they work and what side effects they might have.
For: Hepatocellular CarcinomaUnited States · France · Italy - RecruitingPHASE3
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
This study is looking at a new way to treat bowel cancer that has spread only to the liver. It combines standard chemotherapy with newer targeted drugs, and a special way of delivering chemotherapy directly to the liver, to see if it works better.
For: Colorectal NeoplasmsBelgium · France - RecruitingPHASE2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
This study looks at new treatments (Dostarlimab alone or with Bevacizumab) for certain gynaecological cancers that have come back or not responded to previous treatment, comparing them to standard chemotherapy. It aims to see which treatment works best.
For: Ovarian Neoplasms · Endometrial Neoplasms · Uterine Cervical NeoplasmsAustralia · Hong Kong · Japan - Active not recruitingPHASE1
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
This study is looking into a new treatment for advanced liver cancer (hepatocellular carcinoma) that can't be removed by surgery. It combines a new drug, NP137, with two existing drugs, Atezolizumab and Bevacizumab, to see if it's safe and helps people live longer and respond better to treatment.
For: Hepatocellular CarcinomaFrance - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It aims to find out how safe and effective these treatments are for people whose cancer has specific genetic changes, using blood tests to identify these changes.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
This study looks at new treatments for ovarian cancer that has come back and is resistant to platinum-based chemotherapy. It combines existing drugs like paclitaxel and bevacizumab with a new drug called pembrolizumab, hoping to stop the cancer from growing for longer.
For: Ovarian Cancer · Carcinoma, Ovarian Epithelial · Fallopian Tube NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE2
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
This study looks at using detailed tumour gene testing to guide treatment for advanced breast cancer. It compares giving targeted drugs based on these tests with standard chemotherapy or immunotherapy for patients whose cancer has responded well to initial treatment.
For: Metastatic Breast CancerFrance - RecruitingPHASE2
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that hasn't spread widely. Researchers want to see if adding ONO-4578 and Opdivo® to standard treatment helps more than standard treatment alone. It's for people whose cancer creates a specific protein called PD-L1.
For: Colorectal CancerUnited States · Canada · France - RecruitingPHASE3
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
This study is testing a new medicine, PF-08634404, alongside standard chemotherapy for adults with colorectal cancer that has spread. We want to see if this new combination helps more than an existing treatment with chemotherapy for people whose cancer has returned or spread.
For: Intestinal Neoplasms · Gastrointestinal Neoplasms · Digestive System NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
For: Non-Small Cell Lung Cancer · Colorectal Cancer · Advanced Solid TumorsUnited States · Australia · Belgium